drugset / Trial / NCT07462533
Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing
Phase 2
Not yet recruiting
8 enrolled
Goldman, Butterwick, Fitzpatrick and Groff
Bai Biosciences · collab
RandomizedParallel-groupOpen-labelDiagnostic
Summary
The primary objective of this study is to evaluate the efficacy and tolerability of Pavise Extracellular Matrix Restore (ECMR), compared with standard acute post-operative care, when used as the primary occlusive treatment immediately following ablative CO₂ and Er:YAG facial laser resurfacing to support wound healing.
Timeline
- Start
- 2026-03-20
- Primary completion
- 2026-07-30
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pavise ECMR | Unknown | — | — |